Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398949 | 0.82 | MEN1 (0.61) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL19816585 | 0.82 | MEN1 (0.61) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL19816588 | 0.82 | MEN1 (0.61) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL4038473 | 0.79 | MEN1 (0.58) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL29244286 | 0.78 | MEN1 (0.57) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL7934857 | 0.78 | MEN1 (0.57) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL5643696 | 0.77 | MEN1 (0.75) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL8353840 | 0.77 | LMNA (0.59) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL19965517 | 0.77 | LMNA (0.59) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL8298242 | 0.77 | LMNA (0.59) | MEN1KMT2ALMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604526-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190152978-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152978-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR4, CCR1, CCR3 | MEN1 4835/4885KMT2A 4610/4885LMNA 4831/4885 |
| US-10604526-B2 | Chemokine receptor modulators and uses thereof | CCR4, CCR1, CCR3 | MEN1 4835/4885KMT2A 4610/4885LMNA 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.